{"disease":{"id":"neuroendocrine-carcinoma","name":"neuroendocrine carcinoma"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT00830557","title":"Collecting Medical Information and Tissue Samples From Patients With Pancreatic Cancer or Other Pancreatic Disorders","phase":"","overall_status":"RECRUITING","enrollment_count":20000,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT02628067","title":"Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1609,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":false},{"nct_id":"NCT06663852","title":"ML Decision Model for G-NEC Adjuvant Therapy","phase":"","overall_status":"COMPLETED","enrollment_count":1505,"lead_sponsor_name":"Chang-Ming Huang, Prof.","has_results":false},{"nct_id":"NCT02834013","title":"Nivolumab and Ipilimumab in Treating Patients With Rare Tumors","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":818,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT05671393","title":"the Optimal Surveillance Frequency for Patients With Gastric Neuroendocrine Carcinoma","phase":"","overall_status":"COMPLETED","enrollment_count":801,"lead_sponsor_name":"Fujian Medical University","has_results":false},{"nct_id":"NCT03583528","title":"DOTATOC PET/CT for Imaging NET Patients","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":800,"lead_sponsor_name":"British Columbia Cancer Agency","has_results":false},{"nct_id":"NCT04723095","title":"Establishing a Tumor Registry for Patients With Neuroendocrine Carcinoma of the Cervix","phase":"","overall_status":"RECRUITING","enrollment_count":750,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT03475953","title":"A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":747,"lead_sponsor_name":"Institut Bergonié","has_results":false},{"nct_id":"NCT01365169","title":"Association Between Health Care Provider (HCP)-Assessed ECOG Performance Status (PS) and Overall Survival, and Objectively Measure of Physical Activity (PA) Levels in Advance-cancer Patients\"","phase":"NA","overall_status":"RECRUITING","enrollment_count":590,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT03037385","title":"Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":590,"lead_sponsor_name":"Hoffmann-La Roche","has_results":true},{"nct_id":"NCT02568267","title":"Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":534,"lead_sponsor_name":"Hoffmann-La Roche","has_results":false},{"nct_id":"NCT06683846","title":"Ivonescimab in the Treatment of Multiple Advanced Tumors","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":400,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT04483349","title":"Assessment of What Patients and Healthcare Providers Value","phase":"","overall_status":"COMPLETED","enrollment_count":397,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT03992911","title":"Safety and Efficacy of FOLFSIM Plus Toripalimab in the Treatment of Advanced or Metastatic Neuroendocrine Carcinoma","phase":"PHASE2, PHASE3","overall_status":"UNKNOWN","enrollment_count":336,"lead_sponsor_name":"Peking University","has_results":false},{"nct_id":"NCT06503146","title":"18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":320,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT02611024","title":"Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":316,"lead_sponsor_name":"PharmaMar","has_results":false},{"nct_id":"NCT03866382","title":"Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":314,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT05237934","title":"Tissue Procurement and Natural History Study of Neuroendocrine Neoplasms (NENs) Including Adrenocortical Carcinoma (ACC)","phase":"","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT07410767","title":"Advanced Endoscopic Resections for Rectal Neoplasms","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":300,"lead_sponsor_name":"Jagiellonian University","has_results":false},{"nct_id":"NCT02754297","title":"Personalized PRRT of Neuroendocrine Tumors","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":275,"lead_sponsor_name":"CHU de Quebec-Universite Laval","has_results":false},{"nct_id":"NCT01010126","title":"Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":252,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT03858855","title":"Inhaled Essential Oil Effect on Common QOL Concerns During Cancer Treatment","phase":"NA","overall_status":"COMPLETED","enrollment_count":248,"lead_sponsor_name":"Ohio State University Comprehensive Cancer Center","has_results":false},{"nct_id":"NCT03935893","title":"Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":240,"lead_sponsor_name":"Udai Kammula","has_results":false},{"nct_id":"NCT04471727","title":"A Study in Participants With Advanced Cancers Associated With Expression of DLL3 (MK-6070-001/HPN328-4001)","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":232,"lead_sponsor_name":"Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","has_results":false},{"nct_id":"NCT06577987","title":"Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":220,"lead_sponsor_name":"Circle Pharma","has_results":false},{"nct_id":"NCT05969860","title":"At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":220,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT02709889","title":"Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":200,"lead_sponsor_name":"AbbVie","has_results":true},{"nct_id":"NCT07192991","title":"Neuroendocrine Carcinomas: Patient Journey And Treatment Outcomes In Latin America","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":200,"lead_sponsor_name":"Latin American Cooperative Oncology Group","has_results":false},{"nct_id":"NCT05709171","title":"Dual 64Cu-DOTATATE and 18F-FDG PET/CT Imaging of Patients With Neuroendocrine Neoplasms","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":200,"lead_sponsor_name":"Rigshospitalet, Denmark","has_results":false},{"nct_id":"NCT05015621","title":"A Phase 3 Study to Evaluate Surufatinib Plus Toripalimab in the Treatment of Advanced Neuroendocrine Carcinoma","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":194,"lead_sponsor_name":"Hutchison Medipharma Limited","has_results":false},{"nct_id":"NCT05058651","title":"Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung","phase":"PHASE2, PHASE3","overall_status":"RECRUITING","enrollment_count":189,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT03591731","title":"Nivolumab +/- Ipilimumab in Patients With Advanced, Refractory Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Tumors (NECs)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":185,"lead_sponsor_name":"Intergroupe Francophone de Cancerologie Thoracique","has_results":false},{"nct_id":"NCT06358001","title":"EchoTip AcuCore Post-Market Clinical Study","phase":"","overall_status":"COMPLETED","enrollment_count":183,"lead_sponsor_name":"Cook Research Incorporated","has_results":false},{"nct_id":"NCT06157827","title":"A Clinical Trial of LBL-024 Combined With Etoposide and Platinum in Patients With Advanced Neuroendocrine Carcinoma","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":178,"lead_sponsor_name":"Nanjing Leads Biolabs Co.,Ltd","has_results":false},{"nct_id":"NCT05882058","title":"DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":174,"lead_sponsor_name":"Boehringer Ingelheim","has_results":false},{"nct_id":"NCT01879657","title":"68Ga-DOTATATE PET-CT for Diagnosis of Neuroendocrine Tumors (NETs)","phase":"NA","overall_status":"COMPLETED","enrollment_count":169,"lead_sponsor_name":"Radio Isotope Therapy of America","has_results":false},{"nct_id":"NCT04028479","title":"The Registry of Oncology Outcomes Associated With Testing and Treatment","phase":"","overall_status":"COMPLETED","enrollment_count":167,"lead_sponsor_name":"Taproot Health","has_results":false},{"nct_id":"NCT06424665","title":"A Study of FZ-AD005 in Patients With Advanced Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":162,"lead_sponsor_name":"Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT01642251","title":"Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":156,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT02820857","title":"Assessment of the Efficacy of Bevacizumab in Combination With Folfiri as Second-line Treatment in Patients Suffering From an Advanced Inoperable Poorly Differentiated Neuroendocrine Carcinoma of an Unknown or Gastroentero-pancreatic Primary Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":153,"lead_sponsor_name":"Hospices Civils de Lyon","has_results":false},{"nct_id":"NCT02496208","title":"Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":152,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT03517488","title":"A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":150,"lead_sponsor_name":"Xencor, Inc.","has_results":false},{"nct_id":"NCT06788886","title":"Breathing Practice for Brain and Mental Health in Cancer and Neurodegenerative Diseases","phase":"NA","overall_status":"RECRUITING","enrollment_count":147,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT05337735","title":"A Phase II Clinical Trial to Evaluate Safety and Efficacy of XmAb20717 in Advanced Rare Cancers","phase":"PHASE2","overall_status":"SUSPENDED","enrollment_count":140,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT03110978","title":"Stereotactic Body Radiation Therapy With or Without Nivolumab in Treating Patients With Stage I-IIA or Recurrent Non-small Cell Lung Cancer","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":140,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT03074513","title":"Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":133,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT06937905","title":"Tarlatamab vs Standard of Care Chemotherapy in Patients With Pre-treated Advanced, Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Carcinomas (NECs)","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":129,"lead_sponsor_name":"Intergroupe Francophone de Cancerologie Thoracique","has_results":false},{"nct_id":"NCT01563354","title":"3-arm Trial to Evaluate Pasireotide LAR/Everolimus Alone/in Combination in Patients With Lung/Thymus NET - LUNA Trial","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":124,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT04291885","title":"Immunotherapy Adjuvant Trial in Patients With Stage I-III Merkel Cell Carcinoma","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":122,"lead_sponsor_name":"Melanoma and Skin Cancer Trials Limited","has_results":false},{"nct_id":"NCT07328490","title":"Bispecific T-Cell Engager Tarlatamab and TROP2 Targeted Antibody Drug Conjugate Sacituzumab Govitecan in Previously Treated Extensive-Stage Small Cell Lung Cancer and Extrapulmonary Neuroendocrine Cancer","phase":"PHASE1, PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":120,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}